Point72 Asset Management’s Repare Therapeutics RPTX Stock Holding History

Point72 Asset Management’s Portfolio RPTX Stock Details RPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-51,252	Closed	-$133K	–	4394
2025 Q4	$133K	Buy	+51,252	New	+$103K	﹤0.01%	3705
2023 Q4	–	Sell	-122,300	Closed	-$1.48M	–	2722
2023 Q3	$1.48M	Buy	+122,300	New	+$1.26M	﹤0.01%	1214
2022 Q1	–	Sell	-28,500	Closed	-$601K	–	1360
2021 Q4	$601K	Sell	28,500 -31,198	-52%	-$735K	﹤0.01%	956
2021 Q3	$1.57M	Buy	+59,698	New	+$1.93M	0.01%	806
2021 Q2	–	Sell	-100,000	Closed	-$3.07M	–	1142
2021 Q1	$3.07M	Sell	100,000 -202,584	-67%	-$6.88M	0.01%	666
2020 Q4	$10.4M	Buy	+302,584	New	+$9.04M	0.05%	435
2020 Q3	–	Sell	-15,000	Closed	-$465K	–	1078
2020 Q2	$465K	Buy	+15,000	New	+$482K	﹤0.01%	717

Point72 Asset Management's RPTX Position: Q1 2026 in Review

Point72 Asset Management sold out of Repare Therapeutics (RPTX) in Q1 2026, closing a stake of 51,252 shares — an estimated $133K sold.

Point72 Asset Management first reported a position in RPTX in Q2 2020 and held it in 7 quarters. The position peaked at $10.4M in Q4 2020. 0 funds tracked by Wall St. Rank hold RPTX as of Q1 2026.

Point72 Asset Management reported no remaining Repare Therapeutics position as of Q1 2026 after selling out during the quarter.
Point72 Asset Management sold 51,252 Repare Therapeutics shares in Q1 2026, an estimated $133K.
Point72 Asset Management first reported a position in Repare Therapeutics in Q2 2020 and held it in 7 quarters.
Point72 Asset Management's Repare Therapeutics position peaked at $10.4M in Q4 2020.
0 funds tracked by Wall St. Rank held Repare Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.